Bright Futures: Empowering young adults with inherited sight loss
Join us for an inspiring webinar where young adults living with sight loss share their extraordinary stories and insights.
Search
Search results
Ultra Challenges 2025
With 18 events to choose from in 2025, these hugely popular events are back for another year! Whether you run, jog or walk, you can support Retina UK's vital work whilst achieving an amazing personal goal. Join #TeamRetinaUK today!
Ultra Challenges 2025
With 18 events to choose from in 2025, these hugely popular events are back for another year! Whether you run, jog or walk, you can support Retina UK's vital work whilst achieving an amazing personal goal. Join #TeamRetinaUK today!
Taking on The Thames Path Challenge
Next month, Anisha and Sheena will take on The Thames Path Challenge. Together, they explain why they decided to join #TeamRetinaUK.
Nanoscope Announces topline results from randomised phase 2B trial of MCO-010 for retinitis pigmentosa
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
Meet our volunteers: Dr Katerina Tavoulari
Katerina joined the Retina UK team at the start of 2023 after hearing about the charity through her involvement in a research project at the University of Bath, where she works as an academic.
Meet our supporters: James Clubb
James was part of #TeamRetinaUK in 2020 when he took part in the first ever Virtual London Marathon. He talks about his experience and his motivation.
Meet a researcher: Hassina Zeriri
It’s not very often that we come across a researcher working on a project inspired by their own lived experience of a sight loss condition.
Retina UK-funded discovery leads to $2.5 award for further research
A discovery made as part of research funded by Retina UK has led to a prestigious award of $2.5 million, enabling scientists to undertake more in-depth investigations and work towards a treatment for a particular type of retinitis pigmentosa.
Research update – ProQR
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).